Biosenta (XCNQ:ZRO) Change In Receivables : C$-0.01 Mil (TTM As of Dec. 2024)

View and export this data going back to 2005. Start your Free Trial

What is Biosenta Change In Receivables?

Biosenta's change in receivables for the quarter that ended in Dec. 2024 was C$-0.00 Mil. It means Biosenta's Accounts Receivable increased by C$0.00 Mil from Sep. 2024 to Dec. 2024 .

Biosenta's change in receivables for the fiscal year that ended in Sep. 2024 was C$-0.03 Mil. It means Biosenta's Accounts Receivable increased by C$0.03 Mil from Sep. 2023 to Sep. 2024 .

Biosenta's Accounts Receivable for the quarter that ended in Dec. 2024 was C$0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Biosenta's liquidation value for the three months ended in Dec. 2024 was C$-8.50 Mil.

Biosenta Change In Receivables Historical Data

The historical data trend for Biosenta's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biosenta Change In Receivables Chart

Biosenta Annual Data

Trend

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Sep24

Change In Receivables

Get a 7-Day Free Trial

-0.02

0.03

-0.14

-0.02

-0.03

Biosenta Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Change In Receivables	Get a 7-Day Free Trial															-0.02	-0.05	-0.17	0.21	-

Biosenta Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.01 Mil.

Biosenta (XCNQ:ZRO) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Biosenta's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Biosenta's accounts receivable are only considered to be worth 75% of book value:

Biosenta's liquidation value for the quarter that ended in Dec. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	0.045	-	8.562	+	0.75 * 0	+	0.5 * 0.038
=	-8.50

Biosenta Change In Receivables Related Terms

Thank you for viewing the detailed overview of Biosenta's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Biosenta Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Biosenta Inc (XCNQ:ZRO) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

18 Wynford Drive, Suite 704, Toronto, ON, CAN, M3C 3S2

Website

https://www.biosenta.com

Biosenta Inc is a Canada based company focused on producing and deploying anti-microbial products and remediation solutions to the marketplace for retail, institutional and industrial users. It is engaged in developing sales for its True product lines and the development for commercial applications of its technology to produce an antimicrobial Tri-Filler product. The company's anti-microbial products kill mold, bacteria, and fungi on contact and prevent re-growth. ZeroMold helps contractors to build mold-resistant buildings and provide consumers with a solution to their mold problem. The firm also manufactures and distributes a proprietary anti-microbial filler product for the industrial sector.

Executives

Amarvir Gill	Director, Senior Officer
Dene Rogers	Senior Officer

Biosenta Headlines

No Headlines